Published Technical Disclosure Archive

Enhanced SN-38 Formulations with Poly(amino acid) Block Copolymers

Publication ID: 24-11857630_0001_PTD
Published: October 28, 2025
Category:Direct Improvements & Enhancements

Legal Citation

pr1or.art Inc., “Enhanced SN-38 Formulations with Poly(amino acid) Block Copolymers,” Published Technical Disclosure No. 24-11857630_0001_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857630_0001_PTD
This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,630.

Summary of the Inventive Concept

This inventive concept relates to improved formulations of SN-38 with poly(amino acid) block copolymers, enhancing solubility, stability, and efficacy in cancer treatment.

Background and Problem Solved

The original patent disclosed formulations of SN-38 with poly(amino acid) copolymers, but limitations existed in terms of solubility, stability, and specificity. The new inventive concept addresses these limitations by introducing modifications to the copolymer, such as hydrophilic moieties, specific molecular weights, and targeting moieties, to create more effective and targeted cancer treatments.

Detailed Description of the Inventive Concept

The new inventive concept comprises four key aspects: (1) a system for delivering SN-38 with a poly(amino acid) block copolymer modified with a hydrophilic moiety to enhance aqueous solubility; (2) a method for treating cancer using a formulation with a poly(amino acid) block copolymer engineered to have a specific molecular weight and polydispersity to optimize its pharmacokinetic profile; (3) a pharmaceutical composition with a poly(amino acid) block copolymer functionalized with a targeting moiety to enhance specificity and efficacy; and (4) a process for preparing a SN-38 formulation with improved stability using a sugar-based excipient as a stabilizing agent. These innovations enable the creation of more effective and targeted cancer treatments.

Novelty and Inventive Step

The new inventive concept introduces novel modifications to the poly(amino acid) block copolymer, such as hydrophilic moieties and targeting moieties, which are not disclosed in the original patent. These modifications provide a significant improvement in solubility, stability, and specificity, making the new inventive concept non-obvious and novel compared to the original patent.

Alternative Embodiments and Variations

Alternative embodiments of the inventive concept could include using different types of hydrophilic moieties, varying the molecular weight and polydispersity of the copolymer, or incorporating additional functional groups to enhance targeting and efficacy. These variations would ensure broad conceptual coverage and adaptability to different applications.

Potential Commercial Applications and Market

The enhanced SN-38 formulations with poly(amino acid) block copolymers have significant commercial potential in the cancer treatment market, particularly in the development of targeted and efficacious therapies. The market for cancer treatments is substantial, and the new inventive concept has the potential to capture a significant share of this market.

CPC Classifications

SectionClassGroup
A A61 A61K47/34
A A61 A61K9/08
A A61 A61K9/19
A A61 A61K31/4375
A A61 A61K31/513
A A61 A61K31/519
A A61 A61K45/06
A A61 A61K47/26

Field of Art

Pharmaceutical formulations, specifically cancer drug delivery systems involving camptothecin derivatives like SN-38, with expertise in polymer chemistry, drug encapsulation, and pharmaceutical engineering

Person of Ordinary Skill (PHOSITA) Profile

A researcher with advanced degrees in pharmaceutical sciences or chemical engineering, possessing knowledge of polymer synthesis, drug delivery mechanisms, and cancer treatment formulation techniques

Obviousness Rationale

A person having ordinary skill would recognize that the PTD's modifications to the poly(amino acid) block copolymer represent predictable variations in drug delivery technology. The source patent establishes a foundational framework for SN-38 formulations, and the PTD's proposed enhancements like hydrophilic moieties and targeting groups are well-known strategies in pharmaceutical polymer design. These modifications would be considered routine optimization by a skilled practitioner seeking to improve drug solubility, stability, and targeting.

Obvious Combinations & Variations

Source Patent Element
Composition of SN-38 with poly(amino acid) block copolymer
PTD Variation
Adding hydrophilic moieties to enhance aqueous solubility
Obviousness Reasoning
Improving drug solubility through polymer modification is a standard technique in pharmaceutical formulation, representing a predictable solution to a known problem
Source Patent Element
Basic copolymer composition for drug delivery
PTD Variation
Engineering specific molecular weight and polydispersity to optimize pharmacokinetics
Obviousness Reasoning
Controlling polymer characteristics to modulate drug release and absorption is a well-established approach in controlled drug delivery systems
Source Patent Element
SN-38 formulation with copolymer
PTD Variation
Incorporating targeting moieties to enhance cancer treatment specificity
Obviousness Reasoning
Functionalizing drug delivery polymers with targeting groups is a known strategy for improving therapeutic precision and reducing systemic toxicity
Source Patent Element
Basic pharmaceutical composition
PTD Variation
Using sugar-based excipients as stabilizing agents
Obviousness Reasoning
Selection of stabilizing agents is a routine design choice in pharmaceutical formulation, with sugar-based compounds being well-recognized for their stabilization properties
35 U.S.C. § 103 Summary: Based on US Patent 11857630, the present publication demonstrates that the claimed variations in SN-38 formulation techniques would have been obvious to a person of ordinary skill in the art at the time of invention. The disclosed modifications represent predictable extensions of known drug delivery strategies, utilizing standard polymer engineering techniques to enhance solubility, stability, and targeting of camptothecin derivative compositions.

Original Patent Information

Patent NumberUS 11,857,630
TitleFormulations of SN-38 with poly(amino acid) block polymers
Assignee(s)TYNDALL FORMULATION SERVICES, LLC